Antiretrovirals

Importance of intensive adherence support for people with HIV-related neurological symptoms

17 December 2000. Related: Antiretrovirals.

Efavirenz side effects become long-term for over one in three

17 December 2000. Related: Antiretrovirals, Side effects.

ABT-378/r oral formulation available in UK

17 December 2000. Related: Antiretrovirals.

Trimeris, Roche to begin phase III pivotal trials of T-20 HIV fusion inhibitor

17 December 2000. Related: Antiretrovirals.

United States FDA approves Kaletra for HIV infection

17 October 2000. Related: Antiretrovirals.

Videx EC (ddI, didanosine) – food restrictions

16 September 2000. Related: Antiretrovirals.

Importance of protease inhibitor plasma levels in patients treated with genotypic-guided therapy

16 September 2000. Related: Antiretrovirals.

Flavopiridol inhibits cellular processes essential to replication of HIV

16 September 2000. Related: Antiretrovirals.

Abbott expands early-access program for ABT-378/r (Kaletra)

16 September 2000. Related: Antiretrovirals.

Roche and Trimeris announce intention to manufacture commercial supplies of anti-HIV fusion inhibitor T-20

16 September 2000. Related: Antiretrovirals.

PRO-542 shows efficacy in trial

16 September 2000. Related: Antiretrovirals.

New potential dual NNRTI-based combinations

16 August 2000. Related: Conference reports, Antiretrovirals.

Once-daily protease-based regimens

16 August 2000. Related: Conference reports, Antiretrovirals, Treatment strategies.

European drug approvals: amprenavir, ddI EC, Trizivr and Kaletra

16 August 2000. Related: Antiretrovirals.

DAPD shows activity in vitro against multidrug-resistant HIV but initial results from monotherapy in treatment experienced subjects are disappointing

16 July 2000. Related: Conference reports, Antiretrovirals.

Indinavir/ritonavir at 400/400 mg or 800/100 mg as intensification

16 July 2000. Related: Conference reports, Antiretrovirals.

Ritonavir/saquinavir combination: effect of ritonavir dosage

16 July 2000. Related: Conference reports, Antiretrovirals.

Nevirapine vs efavirenz: the SENC trial

16 July 2000. Related: Conference reports, Antiretrovirals.

Nevirapine daily exposure for daily 400 mg dose compared to 200 mg twice-daily

16 July 2000. Related: Antiretrovirals.

Didanosine systemic exposure in children similar with or without food, high interpatient variability suggests TDM to titrate individual dosages

15 June 2000. Related: Antiretrovirals, Paediatric care.

Low level HIV replication despite good virological response may explain CD4+ cell decline in a patient receiving combination nucleoside analogue therapy

15 June 2000. Related: Antiretrovirals, Basic science and immunology.

ABT-378/r (lopinavir) now available on named patient basis in UK

15 May 2000. Related: Antiretrovirals.

Enteric coated ddI available on named patient basis in UK

15 May 2000. Related: Antiretrovirals.

Nelfinavir potency concerns

15 May 2000. Related: Antiretrovirals.